CD274 and non-small cell lung carcinoma: However, clinical studies have reported that antibodies targeting PD-L1 are an efficacious treatment alternative for patients with advanced NSCLC, who have ≥1% PD-L1 expression [6–8]; studies including more patients with advanced disease would be persuasive and clinically significant in assessing the association between 18F-FDG uptake and PD-L1 expression in NSCLC.